Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives
16 Maggio 2024 - 8:00PM
Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq:
TVGN), a clinical-stage specialty immunotherapy biotech pioneer
developing off-the-shelf, genetically unmodified T cell
therapeutics in oncology, neurology, and virology, announces the
appointment of William Keane as Vice President of Strategic
Initiatives.
Mr. Keane brings 35 years of leadership experience in law
enforcement, having most recently served as the Chief of Police for
Warren, New Jersey, for the past decade. He has also held various
management positions throughout his career. He will work closely
with various functional leads to ensure policies and procedures
conform to current regulatory guidelines and laws. He will also be
instrumental in procuring Tevogen’s lab space to further
operational objectives.
Mr. Keane is a graduate of the FBI National Academy in Quantico,
Virginia, where he received advanced specialized training in
executive management. He also attended the FBI Law Enforcement
Executive Development Seminar in Leadership held at Princeton
University. He was the recipient of the Department Medal of Honor
and numerous departmental commendations during his distinguished
career.
“Mr. Keane’s extensive background in law enforcement, paired
with his natural leadership ability and passion for overseeing
objectives, will play a crucial role in our company's strategic
business decisions as we continue to pioneer the next era of
medical innovation,” remarked Dr. Ryan Saadi.
About Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy company
harnessing one of nature’s most powerful immunological weapons,
CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically
unmodified precision T cell therapies for the treatment of
infectious diseases, cancers, and neurological disorders, aiming to
address the significant unmet needs of large patient populations.
Tevogen Leadership believes that sustainability and commercial
success in the current era of healthcare rely on ensuring patient
accessibility through advanced science and innovative business
models. Tevogen has reported positive safety data from its
proof-of-concept clinical trial, and its key intellectual property
assets are wholly owned by the company, not subject to any
third-party licensing agreements. These assets include three
granted patents and twelve pending patents, two of which are
related to artificial intelligence.
Tevogen is driven by a team of highly experienced industry
leaders and distinguished scientists with drug development and
global product launch experience. Tevogen’s leadership believes
that accessible personalized therapeutics are the next frontier of
medicine, and that disruptive business models are required to
sustain medical innovation.
Contacts
Tevogen Bio CommunicationsT: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/5655e75f-2cb1-4905-9703-93f998195fa9
Grafico Azioni Tevogen Bio (NASDAQ:TVGN)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Tevogen Bio (NASDAQ:TVGN)
Storico
Da Giu 2023 a Giu 2024